ABOUT US

ABOUT US

Telix Pharmaceuticals Limited was established in January 2017 to create a new “theranostics” industry leader. The radiopharmaceutical landscape has historically suffered from lack of commitment to late-stage product development. As such, there are relatively few examples of where proven clinical concepts have made it to the final stages of manufacturing scale-up and commercialisation. Our mission is to rectify this.

Over the past two decades, radiopharmaceutical technologies have developed to a point of clinical maturity, but commercialisation has not yet followed. We believe that this is because of three major issues:

  1. Lack of investment and clinical commitment to running robust late-stage clinical trials (with few exceptions).
    • Our view? We see renewed investor interest in the space and the mainstream pharmaceutical industry can no longer afford to ignore the clinical efficacy of radiopharmaceuticals.
  1. Lack of robust global supply chains guaranteeing that a dose can make it to patients anywhere, every day.
    • Our view? This is changing fast and the advent of new commercially available isotopes such as 177Lu and 89Zr has been transformative to the industry by enabling centralised manufacturing of product.
  1. Lack of integration with “standard care” oncology.
    • Our view? Radiation biology is a major part of oncology care but it can deliver so much more. The “next generation” of oncologists want molecular imaging and targeted radiation strategies as a standard part of their anti-cancer arsenal.

Our team is an experienced group of biopharma clinicians and executives, with a passion for theranostics, radiopharmaceuticals and oncology. We believe that the time for this technology has arrived and that superior efficacy has been demonstrated. Our pipeline currently focuses on unmet needs in cancer care, specifically in prostate, renal (kidney) and glioblastoma (brain) cancer. We are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio.

We are based in Melbourne, Australia. However, the fight against cancer is global, and so is our team. Via our holding company, Telix International Pty Ltd, we conduct R&D, clinical and commercial activities in Australia, USA, Germany, UK and France.

Telix Pharmaceuticals Limited is an unlisted public company.

Management Team

Christian Behrenbruch

Chief Executive Officer

Christian Behrenbruch, B.Eng (Hons) D.Phil (Oxon) MBA JD FIEAust GAICD

Dr Behrenbruch has twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies P/L (a partnership with the Peter MacCallum Cancer Centre). Chris is currently a director of Factor Therapeutics (ASX:FTT) and Amplia Therapeutics P/L. He is Chairman of the Monash Engineering and IT Foundation Board and is an Adjunct Professor at Monash University. Chris holds a D.Phil (PhD) in biomedical engineering from the University of Oxford, an executive MBA jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor (Law) from the University of Melbourne

Douglas Cubbin

Chief Financial Officer

Douglas Cubbin, FCA GAICD

Mr Cubbin is a Certified Practicing Accountant (CPA) with thirty years of experience in finance and executive roles in a diversity of industry sectors, including healthcare, financial services, building, transport/logistics and telecommunications. He is a fellow of the Australian Society of CPAs and a Graduate of the Institute of Company Directors. Doug has spent the last eleven years in CFO, COO, Commercial and Business Development roles in Nuclear Medicine. Prior to that Doug, was the Group CFO of DHL (Australia-Pacific). From 2013 to 2016, Doug was the Chairman of Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine Pty Ltd and the General Manager of Business Development at ANSTO.

Michael Wheatcroft

Director of Research and Development

Michael Wheatcroft, BSc (Hons) PhD (Cantab)

Dr Wheatcroft is Director of R&D at Telix.  After completing a PhD in the Department of Biochemistry, Cambridge University, Mike worked at Cambridge Antibody Technology (now Medimmune,UK), a technology leader in the area of antibody engineering and protein sciences. After moving to Melbourne in 2010 he oversaw the preclinical development of several engineered antibody drug conjugates and clinical translation of novel antibody fragment in prostate and ovarian cancer, including radioimmunoconjugates. Since then Mike has worked in senior development roles at Medicines Development Limited (MDL), Hatchtech P/L and Starpharma Limited where he performed in a variety of managerial roles related to GMP production, clinical study support and nonclinical studies for a range of pharmaceutical and medical device products.

Jyoti Arora

Director of Operations

Jyoti Arora, BAppSc (Hons) PhD

Dr Arora has extensive experience in project management, operations and GMP manufacturing. She holds a PhD in Medical Science and Radiopharmaceutical Chemistry from RMIT University (Melbourne, Australia) and has been involved in both a technical and commercial capacity in a range of translational research projects for novel healthcare technologies. Jyoti also completed a post-doctoral research fellowship at the Peter MacCallum Cancer Centre where she developed and translated novel nanoparticle based imaging technology to the clinic. Prior to joining Telix, Jyoti was a Senior Project Manager at Cell Therapies P/L, with responsibility for overseeing product development of several advanced cell and gene therapy technologies. Her role extended to integrating the use of medical imaging technology in monitoring therapeutic responses of cell based therapies.

Andreas Kluge

Chief Medical Officer

Andreas Kluge, MD PhD

Dr Kluge has 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX-CRO advanced pharmaceuticals, a full service CRO for phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He is also Founder, General Manager and Medical Director for Therapeia GmbH & Co KG, an early-stage development company in the field of neuro-oncology. Andreas has extensive experience in the practice of nuclear medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices. He is the author of numerous patents and publications in the field of nuclear medicine, neurology, infection and immunology. Andreas is a registered physician and holds a doctorate in Medicine from the Free University of Berlin.

Board of Directors

Christian Behrenbruch

Executive Director

Christian Behrenbruch, B.Eng (Hons) D.Phil (Oxon) MBA JD FIEAust GAICD

Dr Behrenbruch has 20 years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies P/L (a partnership with the Peter MacCallum Cancer Centre). Chris is currently a director of Factor Therapeutics (ASX:FTT) and Amplia Therapeutics P/L. He is Chairman of the Monash Engineering and IT Foundation Board and is an Adjunct Professor at Monash University. Chris holds a D.Phil (Ph.D) in biomedical engineering from the University of Oxford, an executive MBA jointly awarded from New York University, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor (Law) from the University of Melbourne.

Andreas Kluge

Executive Director

Andreas Kluge, MD PhD

Dr Kluge has 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX-CRO advanced pharmaceuticals, a full service CRO for phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He is also Founder, General Manager and Medical Director for Therapeia GmbH & Co KG, an early-stage development company in the field of neuro-oncology. Andreas has extensive experience in the practice of nuclear medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices. He is the author of numerous patents and publications in the field of nuclear medicine, neurology, infection and immunology. Andreas is a registered physician and holds a doctorate in Medicine from the Free University of Berlin.

Richard Zimmermann

Non-Executive Director

Richard Zimmermann, PhD

Dr Zimmermann is a chemistry engineer, PhD in Organic Chemistry (Strasbourg), who spent 15 years working in R&D with the conventional pharmaceutical industry first with Beecham (cardiology) then Solvay Pharma (immunology, gastroenterology) before joining in 1998 the radiopharmaceutical industry as R&D Director with CISbio international (Saclay). Richard was responsible for building the European PET/FDG manufacturing network for CIS/IBA and took the position of VP Business Development for IBA Molecular. In 2012, Richard established Chrysalium Consulting, which provides specialized consulting expertise in radiopharmaceutical development and industrialization. Richard is cofounder of MEDraysintell, President of the Oncidium foundation, a co-founder of Rad4med.be, and Chairman of two early-stage companies, Medisystem and ANMI.

Oliver Buck

Non-Executive Director

Mr Buck is a bio-physicist who has spent his professional career in a variety of entrepreneurial and management positions in industrial companies. Oliver has served as founder, managing director and developer of several companies in the fields of manufacturing, technology, demilitarization, pharmaceutical and information technologies. Oliver is the co-founder of ITM Isotopen Technologien München AG, one of the largest isotope manufacturing and distribution companies in the world, founded with Technical University of Munich. Since 2012, Oliver has acted as senior advisor to the CEO in a role that continues to support the ITM Group as it has become a leader in next generation medical isotopes and theranostics. Oliver holds a graduate degree in theoretical physics from the Technical University of Munich and is an alumnus of the German National Academy for Security Policy and the “Young Leaders Program” of the Atlantik Brücke/ American Council on Germany.

Michael Cawley

Non-Executive Director

Michael Cawley, B.Comm CA

Mr. Cawley is an equity capital markets advisor to Telix and serves as an interim director of the company. Michael is responsible for the execution of Equity Capital Markets transactions in the Sydney office of Taylor Collison Limited. He has over 15 years of experience advising listed and unlisted corporations in relation to their capital requirements and has completed numerous initial public offerings, secondary placements, rights issues and capital management advisory assignments. Michael is a member of The Institute of Chartered Accountants in Australia and holds a Bachelor of Commerce from The University of Western Australia.

Melanie Farris

Company Secretary

Melanie Farris, BComm AGIA ACIS

Ms. Farris is an experienced governance, communications and operations executive. Currently a non-executive director for Synapse Australia Limited, and in governance and operations roles with Factor Therapeutics Limited (ASX:FTT) and Invion Limited (ASX:IVX), previous roles include with HRH The Prince of Wales’s Office, Global Asset Management, Imperial Cancer Research Fund, and The Prince’s Foundation. Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is an Associate of the Governance Institute of Australia and an Associate of the Institute of Chartered Secretaries (UK).

Leading Scientific Advisory Board

Rodney Hicks

Rodney Hicks, MBBS MD

Professor Hicks is Professor of Medicine and Radiology at the University of Melbourne; Director of the Centre for Cancer Imaging at the Peter MacCallum Cancer Centre; and Co-Chair of the Neuroendocrine Service. Rodney’s group, with its strong focus on translational research and drug development, established the first pre-clinical PET imaging facility in Australia. Rodney is Editor-in-Chief of Cancer Imaging, and serves on eight other editorial boards including Endocrine-Related Cancer. He has over 400 peer-reviewed publications, and holds numerous national and international research grants including a major translational research grant from the Victorian Cancer Agency to develop new diagnostic and therapeutic approaches for this group of diseases. Rodney received a prestigious National Health and Medical Research Council Program Grant in 2013 and an NHMRC Practitioner Fellowship in 2015. He was also inducted as a Fellow of the Australian Academy of Health and Medical Science in 2015.

Selected Publications

Citius, altius, fortius: An olympian dream for theranostics.  Journal of Nuclear Medicine.  58. 2017

Cousins not twins: Intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours.  Journal of Pathology.  2017

Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14.  Haematologica.  102. 2017

PET Imaging for Endocrine Malignancies: From Woe to Go..  Journal of Nuclear Medicine.  58. 2017

THYROPET study: Is it biology or technology that is the issue?.  Journal of Nuclear Medicine.  58. 2017

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.  The Oncologist.  22. 2017

Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?.  Journal of Nuclear Medicine.  58. 2017

Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of alpha(v)beta(3) Integrin Expression with Gallium-68.  Bioconjugate Chemistry.  28. 2017

Sulfonation of Tyrosine as a Method To Improve Biodistribution of Peptide-Based Radiotracers: Novel F-18-Labeled Cyclic RGD Analogues.  Molecular Pharmaceutics.  14. 2017

A Phase IIa Randomized Control Trial of VEL015 ( Sodium Selenate) in Mild-Moderate Alzheimer’s Disease.  Journal of Alzheimer’s Disease.  54. 2016

Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.  Oncotarget.  7. 2016

BRAF Inhibition in BRAF(V600E)-Positive Anaplastic Thyroid Carcinoma.  Journal of the National Comprehensive Cancer Network.  14. 2016

Does PET SUV Harmonization Affect PERCIST Response Classification?.  Journal of Nuclear Medicine.  57. 2016

Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning 2016

Ga-68-DOTATATE and F-18-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.  Cancer Imaging.  16. 2016

Gallium-68 EDTA PET/CT for Renal Imaging.  Seminars in Nuclear Medicine.  46. 2016

Jean-Francois Chatal

Jean-François Chatal, MD PhD

 

Professor Jean-François Chatal is a Distinguished Professor of Nuclear Medicine at the University of Nantes, France. He has written 203 original papers and presented more than 150 invited lectures in his career, which began with the creation of a research team devoted to diagnostic and therapeutic use of radiolabeled monoclonal antibodies in oncology. He served as head of Nuclear Medicine Departments at the University Hospital and Cancer Centre in Nantes France. Jean-François’s collaboration with Immunotech in Marseille saw the preclinical and clinical application of an original and innovative pretargeting technology based on the use of unlabeled bispecific antibody and radiolabeled bivalent hapten, which led to a 2006 paper published in the Journal of Clinical Oncology that reported, for the first time, a survival benefit of pretargeted radioimmunotherapy in an advanced solid tumor (medullary thyroid carcinoma). With two colleagues at the University of Nantes, Jean-François initiated the installation of a high energy/ high intensity cyclotron, termed ARRONAX, for the production of innovative radionuclides for nuclear medicine. He also contributed to the creation of Atlab-Pharma, a company dedicated to the industrial development of radiolabeled antibodies for radioimmunotherapy. In 2013, he was honored in Paris by the “Antoine Beclere medal” granted for his work in Nuclear Medicine development.

 

Selected Publications

Clément Bailly, Pierre-François Cléry , Alain Faivre-Chauvet, Mickael Bourgeois, François Guérard, Ferid Haddad, Jacques Barbet, Michel Chérel, Françoise Kraeber-Bodéré, Thomas Carlier and Caroline Bodet-Milin, Immuno-PET for Clinical Theranostic Approaches  International Journal of Molecular Sciences 18(1):57 · December 2016

Françoise Kraeber Bodere , Jacques Barbet , Jean-François Chatal Radioimmunotherapy: from current clinical success to future industrial breakthrough? Journal of Nuclear Medicine · October 2015

Chatal J-F, Rouzet F, Haddad F, Bourdeau C, Mathieu C and Le Guludec D (2015) Story of rubidium-82 and advantages for myocardial perfusion PET imaging. Front. Med. 2:65.

Chatal J. F., Perkins A. C., Baum R. P., Bischof Delaloye A., Prior J., Signore A. The long history of the International Research Group in Immuno-Scintigraphy and Therapy (IRIST) The quarterly journal of nuclear medicine and molecular imaging: June 2015

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Frampas E, Faivre-Chauvet A, Rauscher A, Sharkey RM, Goldenberg DM, Chatal J-F and Barbet J (2015) A pretargeting system for tumor PET imaging and radioimmunotherapy. Front. Pharmacol. 6:54.

 Activities in the Scientific Community / Professional Memberships (selection)

Board of Directors, Society of Radiopharmaceutical Sciences (2013-present); President-Elect, World Molecular Imaging Society (2013-14); Member, Specialized Imaging Research Consortium of the National Comprehensive Cancer Network (NCCN) (2014-15); President, World Molecular Imaging Society         (2014-15); Member, AACR Award for Outstanding Achievement in Chemistry in Cancer Research Committee (since 2015); Board of Directors, Academy of Radiology Research (since 2016).

Honours and Awards (selection)

2013 Antoine Beclere Medal

Jason Lewis

Jason Lewis, BSc MSc PhD

 

Professor Jason Lewis serves as Vice Chair for Research and Chief of the Radiochemistry & Imaging Sciences Service in Memorial Sloan Kettering’s Department of Radiology, and Director of Memorial Sloan Kettering’s Radiochemistry and Molecular Imaging Probe Core Facility. Jason is a Member in Memorial Sloan Kettering, head of a laboratory in the Sloan Kettering Institute’s Molecular Pharmacology Program, and a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Jason has published over 160 papers, books, book chapters, and reviews in the field of cancer imaging. He serves on grant review panels for the National Institutes of Health/National Cancer Institute and on a number editorial boards. Professor Lewis holds a PhD from The University of Kent (UK).

 

Selected Publications

Ulmert HD, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson P-A, Scardino PT, Larson SM, Lilja H, Lewis JS*, Sawyers CL*. Imaging androgen receptor signalling with a radiotracer targeting free prostate specific antigen. Cancer Discovery, 2, 320-327, 2012. (*co-corresponding senior authors). (Cover Article)

Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL and Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. Journal of Nuclear Medicine, 54:90-95, 2013. (Cover Article)

Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak K, Drobnjak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology. Journal of Nuclear Medicine, 54:1876-1882, 2013. (Cover Article)

Brand C, Abdel-Atti D, Yachao Z, Carlin SD, Clardy SM, Keliher EJ, Weber WA, Lewis JS, Reiner T. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjugate Chem, 25, 1324-1330, 2014. (Cover Article)

Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS*, Evans MJ*. Applying 89Zr-transferrin to study the pharmacology of inhibitors to BET bromodomain containing proteins. Molecular Pharmaceutics, 13, 683-688, 2016. (*co-corresponding senior authors). (Selected as an ACS Editors’ Choice article)

Houghton JL, Zeglis BM, Abdel-Atti D, Sawada R, Scholz WW, Lewis JS. Pretargeted immunoPET of pancreatic cancer: overcoming circulating antigen and antibody internalization to reduce radiation doses. Journal of Nuclear Medicine, 57, 453-459, 2016. (Cover Article)

Sharma SK, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, Sala E, Zeglis BM,*, Lewis JS*. Preclinical 89Zr-immunoPET of High Grade Serous Ovarian Cancer and Lymph Node Metastasis. Journal of Nuclear Medicine, 57, 771-776, 2016. (*co-corresponding senior authors) (Cover Article)

Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta M, Pourat J, Longo VA, Carlin SD, Engelman DM, Andreev OA, Reshetnyak YK, Viola-Villegas N, Lewis JS. PET Imaging of Extracellular pH in Tumors with 64Cu- and 18F-labeled pHLIP peptides: A Structure-Activity Optimization Study. Bioconjugate Chemistry, 27, 2014-2023, 2016. (Cover Article)

Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, Zanzonico PB, Lewis JS, Zeglis BM. Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. Molecular Cancer Therapeutics, 16, 124-133, 2017. (Cover Article)

Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, Liu D, Zeglis BM, Rudin CM, Dylla SJ, Poirier JT, Lewis JS. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research, in press, 2017. (*co-corresponding senior authors)

 

Activities in the Scientific Community / Professional Memberships (selection)

Board of Directors, Society of Radiopharmaceutical Sciences (2013-present); President-Elect, World Molecular Imaging Society (2013-14); Member, Specialized Imaging Research Consortium of the National Comprehensive Cancer Network (NCCN) (2014-15); President, World Molecular Imaging Society         (2014-15); Member, AACR Award for Outstanding Achievement in Chemistry in Cancer Research Committee (since 2015); Board of Directors, Academy of Radiology Research (since 2016).

Honours and Awards (selection)

2013 Berson-Yalow Award (Co-Senior Author), Society of Nuclear Medicine and Molecular Imaging

2014 JNM Editors’ Choice Award for best basic science investigation

2014 Distinguished Investigator Award from the Academy of Radiology Research

2015 Fellow, World Molecular Imaging Society

2017 SNMMI Michael J. Welch Award

2017 Elected Member, International Society for Strategic Studies in Radiology (IS3R)

Klaus Kopka

Klaus Kopka, PhD

Professor Klaus Kopka holds a full Professorship (W3) at the Ruprecht-Karls-University of Heidelberg, Germany, and is head of the Division of Radiopharmaceutical Chemistry of the German Cancer Research Centre (dkfz) Heidelberg, Germany. His research focuses on radiopharmaceutical sciences with focus on radiopharmaceutical drug development in combination with medicinal chemistry, in recent years directed to the development of novel theranostic radiotracers targeting the prostate-specific membrane antigen (PSMA). Since 2012 Klaus has been the Chairman of the Working Group Radiochemistry / Radiopharmacy (AGRR) Committee of the German Association of Nuclear Medicine (DGN). He was honoured with the Young Molecular Cardiovascular Imaging Award of the North Rhine-Westphalian Academy of Sciences (Duesseldorf). He is author and co-author of more than 120 publications and inventor and co-inventor on more than 10 published patents, primarily dealing with the development of new PET tracers and radiopharmaceuticals for endoradiotherapy. Currently, Klaus is the radiopharmaceutical coordinator of the prospective multi-centre clinical trial of the German Cancer Consortium (DKTK) 68Ga-PSMA-11 in high-risk prostate cancer. This endeavour, dealing with accurate prostate PET imaging, is recognized as one of the defined DKTK highlight projects.

 

Selected Publications

Giesel FL, et al. Kopka K*, Kratochwil C*. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017, 44: 678-688. *contributed equally.

Cardinale J, et al. Kopka K. Preclinical Evaluation of 18F-PSMA-1007: A New PSMA-Ligand for Prostate Cancer Imaging. J Nucl Med 2017, 58: 425-431.

Liolios CC, et al. Kopka K. Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer. Bioconjugate Chem 2016, 27: 737-751.

Benešová M, et al. Kopka K*, Eder M*. Linker Modification Strategies to Control the Prostate-specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. J Med Chem 2016, 59: 1761-1775. *contributed equally

Schrigten D, et al., Kopka K. A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-targeted Radiotracers for Positron Emission Tomography. J Med Chem 2012, 55: 223-232.

 

Activities in the Scientific Community / Professional Memberships (selection)

Co-Ed. Textbook Nuklearmedizin (8th ed. 2017, Schattauer); Assoc. Ed. Pharmaceuticals (MDPI) (since 2017); Guest Ed. SI in Pharmaceuticals (2017, 2015); Ed. Board EJNMMI RadPharm & Chem (since 2015); Member PhD thesis committee Dr. sc. hum. Medical Faculty Heidelberg (since 2013); Chairman of Working Group Radiochemistry / Radiopharmacy (AGRR, >365 registered members) (since 2012); Member SRS, ACS, GDCh, DGN; Reviewer of >10 journals; Reviewer BFS, DFG, STW, NCCBI, SNF, aka.fi; Congress President AGRR2008; HL-Lecturer NuklearMedizin2014; founding member EIMI (2007); >10 published patents; 15 invited lectures/key note lectures since 2013.

Honours and Awards (selection)

2016     Roland-Ernst-Award (Cardinale, Schäfer), DKFZ Heidelberg, Germany.

2015     Berson-Yalow-Award (Eder et al.); Image of the Year Award (Benešová et al.), SNMMI, USA.

2006     Young Molecular Cardiovascular Imaging Award; NRW Academy of Science, Germany.

Neil Bander

Neil Bander, MD PhD

 Dr Bander is a physician-scientist trained in urological oncology and tumour immunology, at Memorial Sloan-Kettering Cancer Centre (NY). After joining the faculty of Cornell University Medical College (now Weill-Cornell Medical College) and New York-Presbyterian Hospital, he has directed both a laboratory effort and translational clinical research program to discover and clinically develop monoclonal antibodies for targeted cancer imaging and therapy. He currently holds the Bernard and Josephine Chaus Chair in Urological Oncology and is Director of Urological Oncology Research at Weill Cornell where he is a tenured Professor and a Member, Department of Surgery (Urology) at Memorial Sloan-Kettering Cancer Centre. Neil’s team has the world’s largest experience in antibody discovery and clinical development in urological oncology. His group developed the first series of monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could target and bind viable prostate cancer cells. In large part as a result of Neil’s efforts, PSMA has become recognized as the most prostate-cancer specific cell surface antigen known and a target of significant interest in academia and bio-pharma. His team and collaborators have developed PET imaging agents as well as radiolabeled- and drug-conjugated antibodies that have entered phase 1 and 2 clinical trials now extending to a dozen leading academic medical centres in the US and Europe. Neil’s collaborations extend beyond academia and he has, and continues to, serve as a consultant and Advisory Board member to several bio-pharmaceutical companies. He is a past member of the Weill Cornell-Pfizer Centre for Technological Innovation Joint Steering Committee. Antibodies developed in his lab have been licensed to multiple bio-pharma companies for further development and commercialization. Neil has authored approximately 175 peer-reviewed publications, and he is an inventor on approximately 100 US and foreign issued and pending patents. He has served on, and chaired, multiple study sections and grant review panels.

 

Selected Publications

Milowsky, M.I., Galsky, Matthew D. M.D., Morris, Michael J., Crona, Daniel J. George, Daniel J.

Dreicer, Robert, Tse, Kin, Petruck, Jesika, Webb, Iain J., Bander, Neil H., Nanus, David M, Scher, Howard.  Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.  Urologic oncology. 2016

 

Fung, Edward K., Cheal, Sarah M., Fareedy, Shoaib B., Punzalan, Blesida, Beylergil, Volkan, Amir, Jawaria, Chalasani, Sandhya, Weber, Wolfgang, Spratt, Daniel E., Veach, Darren R., Bander, Neil H., Larson, Steven Mark, Zanzonico, P.B., Osborne, Joseph R. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.  Cancers.  2016.

 

Nguyen, Daniel P., Xiong, Peter L., Liu, He, Pan, Samuel, Leconet, Wilhem, Navarro, Vincent, Guo, Ming, Moy, Jonathan, Kim, S., Ramirez-Fort, Marigdalia K., Batra, Jaspreet S., Bander, Neil H.. Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.  Molecular cancer research : MCR. 2016

 

Crowley, M.J.P. Scognamiglio, Theresa, Liu, Yi Fang, Kleiman, D.A., Beninato, Toni M., Aronova, A.

Liu, He, Jhanwar, Yuliya S, Molina, Ana M., Tagawa, Scott T., Bander, Neil H., Zarnegar, Rasa, Elemento, Olivier, Fahey, Thomas J. Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.  The Journal of clinical endocrinology and metabolism.  2016

 

Wernicke, Gabriella A., Kim, S., Liu, H, Bander, Neil H., Pirog, Edyta Catalina. Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.  Applied immunohistochemistry & molecular morphology : AIMM. 2016

 

McNeel, Douglas G., Bander, Neil H., Beer, Tomasz M., Drake, Charles G., Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip, Madan, Ravi A., Oh, William K., Peace, David, Petrylak, Daniel P., Porterfield, Hank, Sartor, Oliver, Shore, Neal D., Slovin, Susan Faith, Stein, Mark, Vieweg, Johannes

Gulley, James L. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.  Journal for ImmunoTherapy of Cancer.  2016 Academic Article GET IT

 

Honours and Awards (selection)

2012 – 2017 Clinical and Translational Science Centre (UL1) – Cooperative Agreement awarded by National Centre for Advancing Translational Science

 

2011 – 2014 Anti-Prostate-Specific Membrane Antigen-Duocarmicin Conjugates for Targeted Therapy of Advanced Prostate Cancer awarded by United States Department of Defense Principal Investigator

 

2010 Radiolabeled Anti-PSMA Monoclonal Antibody to Target Non-Prostate Solid Tumor Neovasculature awarded by Elsa U. Pardee Foundation Key Personnel

 

2009 – 2012 A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate Biochemically Relapsed…  awarded by United States Department of Defence

Chaitanya Divgi

Chaitanya Divgi, MS MBBS

 

Dr Divgi is former Director, Nuclear Medicine and PET and Vice-Chair, Research, Department of Radiology at Columbia University. After graduating from St. John’s Medical College in Bangalore, India, Chaitanya joined the Radiation Medicine Centre, Bhabha Atomic Research Centre, Bombay, where he obtained a Diploma in Radiation (Nuclear) Medicine. He joined the University of Pennsylvania as Chief of Nuclear Medicine and Clinical Molecular Imaging in May 2006, where he was awarded a NCRR high-end instrumentation grant for an isotope production cyclotron. Chaitanya joined Columbia University in 2011, where he has rejuvenated the PET/CT program and instituted a comprehensive University-wide IND centre that has successfully obtained approval for numerous agents used in neuroscience and oncology research. Chaitanya is involved in educational and policy initiatives, in particular the successful integration of diverse Investigational New Drug applications into one centre, under his supervision, that was responsible for all IND applications utilizing radiopharmaceuticals at Penn and Columbia.

 

Selected Publications

Neeta Pandit-Taskar, Joseph A O’Donoghue , Chaitanya R Divgi, Eze A Wills, Lawrence Schwartz , Mithat Gönen, Peter Smith-Jones, Neil H Bander, Howard I Scher, Steven M Larson and Michael J Morris. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research (2015) 5:28

 

Chunsheng Li, Ann-Marie Chacko, Jia Hu, Kosei Hasegawa, Jennifer Swails, Luigi Grasso, Wafik S ElDeiry, Nicholas Nicolaides, Vladimir R Muzykantov, Chaitanya R Divgi & George Coukos (2014) Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model, Cancer Biology & Therapy, 15:4, 443-451

 

 

Nicolaides, Vladimir R. Muzykantov, Chaitanya R. Divgi and George Coukos Ann-Marie Chacko, Chunsheng Li, Madhura Nayak, John L. Mikitsh, Jia Hu, Catherine Hou, Luigi Grasso, Nicholas C. Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin. J Nucl Med. 2014;55:500-507.

 

Christine A. Ciunci, MD; Rodolfo F. Perini, MD; Anjali N. Avadhani, MD ; Hyunseon C. Kang, MD; Weijing Sun, MD ; Maryann Redlinger, RN ; Kathleen Harlacker,; Keith T. Flaherty, MD ; Bruce J. Giantonio, MD; Mark A. Rosen, MD, PhD; Chaitanya R. Divgi, MD; Hee Kwon Song, PhD ; Sarah Englander, PhD; Andrea Troxel, ScD; Mitchell Schnall, MD; and Peter J. O’Dwyer, MD. Phase 1 and Pharmacodynamic Trial of Everolimus in Combination With Cetuximab in Patients With Advanced Cancer. Cancer · January 2014

 

Joseph A O’Donoghue1, José G Guillem, Heiko Schöder, Nancy Y Lee, Chaitanya R Divgi, Jeannine A Ruby, John L Humm, Steven A Lee-Kong, Eva M Burnazi, Shangde Cai, Sean D Carlin, Tobias Leibold, Pat B Zanzonico and C Clifton Ling. Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. EJNMMI Research 2013, 3:42

 

Lilie L. Lin, Antti Silvoniemi, James B. Stubbs, Ramesh Rengan, Sami Suilamo, Olof Solin, Chaitanya Divgi, Olli Eskola, Jonathan M. Sorger, Michael G. Stabin, Alexander Kachur, Stephen M. Hahn, Tove J. Gro¨ nroos, Sarita Forsback, Sydney M. Evans, Cameron J. Koch, and Heikki Minn. Radiation Dosimetry and Biodistribution of the Hypoxia Tracer 18F-EF5 in Oncologic Patients. Cancer Biotherapy & Radiopharmaceuticals · August 2012

Samuel Samnick

Samuel Samnick, PhD

Professor Samuel Samnick is the Head of the Interdisciplinary PET Centre and Radiopharmacy at the Department of Nuclear Medicine of the University Würzburg (Germany). Upon completion of an engineering degree (1988) at the University of Applied Sciences Nuremberg, he obtained his Diploma in Bio-organic chemistry at the University of Osnabrück (1991), and a PhD on the development and validation of specific radiotracers for addressing receptors in neurological diseases using PET and SPECT (1994) at the Department of Nuclear Medicine of the University Münster, Germany. He pursued his post-doctoral studies (1994-1997) at the Centre for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen/Zurich, Switzerland, and at the Ludwig Institute for Cancer Research, Melbourne, Australia. In 1997 he joined the Department of Nuclear Medicine at the University of Saarlandes (Germany) as head of the radiopharmaceutical research and accomplished his habilitation (2001) in Experimental Nuclear Medicine and Radiopharmaceutical Chemistry, followed by an appointment as Assistant Professor in Radiopharmaceutical Sciences (2001) and as Apl. Professor (2005) at the University Medical School, Homburg/Saar (Germany). In 2007, he was appointed as Full Professor for Experimental Nuclear Medicine and Radiopharmacy and Head of the Interdisciplinary PET-Centre at the Julius-Maximilians University Würzburg (Germany).

 

Selected Publications

Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics. 2017 Apr 8;7(6):1589-1597.

 

Lapa C, Schreder M, Lückerath K, Samnick S, Rudelius M, Buck AK, Kortüm KM, Einsele H, Rosenwald A, Knop S. Methionine emerges as a new biomarker for tracking active myeloma lesions. Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14696.

 

Lapa C, Schirbel A, Samnick S, Lückerath K, Kortüm KM, Knop S, Wester HJ, Buck AK, Schreder M. The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1097-1098

 

Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, Lückerath K. Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma – Comparison to [18F]FDG and laboratory values. Theranostics. 2017 Jan 1;7(1):205-212

 

Werner RA, Weich A, Schirbel A, Samnick S, Buck AK, Higuchi T, Wester HJ, Lapa C. Intraindividual tumor heterogeneity in NET – Further insight by C-X-C motif chemokine receptor 4-directed imaging. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):553-554. doi: 10.1007/s00259-016-3566-3. Epub 2016 Nov 9. No abstract available.

 

Maya Y, Werner RA, Schütz C, Wakabayashi H, Samnick S, Lapa C, Zechmeister C, Jahns R, Jahns V, Higuchi T. 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis. J Nucl Med. 2016 Dec;57(12):1985-1990

 

Sawatzky E, Al-Momani E, Kobayashi R, Higuchi T, Samnick S, Decker M. A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety. ChemMedChem. 2016 Jul 19;11(14):1540-50

 

Activities in the Scientific Community / Professional Memberships (selection)

The development and validation of innovative radiopharmaceuticals for molecular imaging using PET and SPECT for neurological, oncological and cardiovascular research, and for endo-radionuclide therapy, and translational and clinical research.

Richard Baum

Richard Baum, MD PhD

 

Professor Richard Baum is Professor of Nuclear Medicine at the University of Frankfurt/Main Germany; and Chairman and Clinical Director, Department of Nuclear Medicine / Center for PETCT, Zentralklinik Bad Berka. Richard was appointed “Visiting Professor” of the FM Medical University (Tandu Hospital) in Xi’an, Shaanxi, China where he initiated a project on Ga-68 imaging and PRRNT for the first use in China of theranostics. Honoured by the Society of Nuclear Medicine for his “Life Time Contribution to The Field of Nuclear Medicine”, Richard is a referee of many scientific journals and has had 227 original papers in peer reviewed journals and 114 papers in proceedings books. He is Editorial Board Member of several journals including Journal of Nuclear Medicine, European Journal of Nuclear Medicine, International Journal of Biological Markers Tumor Targeting Radiation Oncology, and has served as Member of the Executive Committee of the World Radiopharmaceutical Council (WRPTC) of the World Federation of Nuclear Medicine and Biology.

 

Selected Publications

Baum RA, Baum S. Interventional radiology: a half century of innovation. Radiology. 2014 Nov; 273(2 Suppl):S75-91. PMID: 25340439.

 

Baum R, Bertsimas D, Kallus N. Scheduling, revenue management, and fairness in an academic-hospital radiology division. Acad Radiol. 2014 Oct; 21(10):1322-30. PMID: 25088836.

 

Pamarthi V, Stecker MS, Schenker MP, Baum RA, Killoran TP, Suzuki Han A, O’Horo SK, Rabkin DJ, Fan CM. Thoracic duct embolization and disruption for treatment of chylous effusions: experience with 105 patients. J Vasc Interv Radiol. 2014 Sep; 25(9):1398-404. PMID: 24837980.

 

Todorovic-Tirnanic M, Kaemmerer D, Prasad V, Hommann M, Baum RP. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Recent Results Cancer Res. 2013; 194:487-96. PMID: 22918778.

 

Kis B, Pamarthi V, Fan CM, Rabkin D, Baum RA. Safety and utility of transjugular liver biopsy in hematopoietic stem cell transplant recipients. J Vasc Interv Radiol. 2013 Jan; 24(1):85-9. PMID: 23200125.

 

Swietaszczyk C, Prasad V, Baum RP. Intense 18F-fluoride accumulation in liver metastases from a neuroendocrine tumor after peptide receptor radionuclide therapy. Clin Nucl Med. 2012 Apr; 37(4):e82-3. PMID: 22391729.

 

Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, Hommann M. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med. 2012 Feb; 37(2):142-7. PMID: 22228336.

 

Hörsch D, Sayeg Y, Bonnet R, Kaemmerer D, Presselt N, Baum RP. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system]. Pneumologie. 2012 Jan; 66(1):44-8. PMID: 22250054.

 

Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012 Mar; 39(3):501-11. PMID: 22183108.

 

Honours and Awards (selection)

1986 Board Election, International Research Group in Immunoscintigraphy and immunotherapy(IRIST), Consultant, International Atomic Energy Agency (IAEA)

1989 Election, President of IRIST, Mallinckrodt Award (German Society of Nuclear Medicine)

1991 Election, Advisory Council of the EANM Chief Scientific Investigator of the IAEA

1996 Sharabai Memorial Oration Award, Society of Nuclear Medicine India

1999 EANM Committee Oncology

2001 Annual Lecture, British Nuclear Medicine Society

2003 Docente Especial de Professor Invitado” del Inst. Sup. de Ciencias Med. Habana/Cuba

2006 Member of the Executive Committee of the World Radiopharmaceutical Council (WRPTC) of the World Federation of Nuclear Medicine and Biology

2009 Key Note Speaker Canadian Nuclear Medicine Society Invited Lecturer, British Society of Nuclera Medicine for delivering “The Future” lecture

2010 F.Y. Khoo Lectureship and Medal, Academy of Medicine & Singapore Radiological Society, Singapore

Activities in the Scientific Community / Professional Memberships (selection)

German Society of Nuclear Medicine, Scientific Secretary of the Annual Congress 1990; European Association of Nuclear Medicine, Member, Advisory Board (1991 -); Member, Task Group CURA (1988-); Member, JETGURT (1990-1991); Member, Scientific Program Committee (1989, 2001); Steering Committee Member, European PET Institute of the EANM; Lecturer, European School of Nuclear Medicine, Society of Nuclear Medicine (USA), British Nuclear Medicine Society (BNMS), European School of Oncology (ESO); Faculty Member, European Society for Medical Oncology (ESMO), Deutsche Krebshilfe (German Cancer Society); International Research Group in Immunoscintigraphy and Immunotherapy (IRIST); International Society of Radiolabelled Blood Elements (ISORBE).